Glaukos Reports Three-Year Epioxa Data in Keratoconus

Simply Wall St··US·Read original
3▲1 ▼0Impact / 5
Summary · why it matters

Glaukos reported positive topline results from a long-term Phase 3 extension study of Epioxa, showing three-year durable efficacy, clinically meaningful visual gains, and no serious safety issues in keratoconus patients after a single epi-on corneal cross-linking treatment. The company also raised its 2026 net sales guidance to US$680 million to US$700 million, helped by contributions from iDose TR and Epioxa. Glaukos' narrative projects $1.2 billion revenue and $132.4 million earnings by 2029, while the most cautious analysts assumed about US$1.0 billion of revenue and only US$75.5 million of earnings by 2029. The new long-term Epioxa results support the idea that corneal therapies can be a meaningful second pillar alongside glaucoma, though they sit within the same execution and reimbursement risks that already define the main catalysts for the stock.

Impact on assets 1

Aging Population▲
Glaukos Corp
GKOS
▲ PositiveCapitalTechnologyrelevance

Glaukos raised its 2026 net sales guidance to $680-700 million, helped by iDose TR and Epioxa contributions.

Theme Impact 1

Related news

United States
▲2

Glaukos iDose TR Hits Primary Goal in Phase 4 Glaucoma Trial

Glaukos Corp. said its iDose TR travoprost intracameral implant met the primary goal of a phase 4 trial in patients with open-angle glaucoma or ocular hypertension. At three months, participants who underwent cataract surgery and received iDose TR saw a mean diurnal intraocular pressure reduction of 11.1 mmHg from baseline, compared with 7.4 mmHg for those who had cataract surgery alone. The iDose TR arm was also superior to cataract surgery alone in secondary responder analyses. No treatment-related adverse events of corneal endothelial cell loss, cystoid macular edema, or serious corneal adverse events were reported. iDose TR is designed to provide a continuous supply of travoprost inside the eye for up to three years.
About megatrends
Aging Population › Vision & Eye Care ▲Technology
GKOS · Technology · Positive iDose TR met the primary endpoint in a Phase 4 glaucoma trial, showing superior intraocular pressure reduction with no serious adverse events.
Read original ↗
Seeking Alpha·1dRead more →
China

Huaxia Eye Hospital appoints Yang Weilai as board secretary; former secretary Cao Naien resigns

Huaxia Eye Hospital announced on October 9 that former board secretary Cao Naien resigned for personal reasons and will no longer hold any position at the company. The company's board of directors held a meeting on October 9, 2026, and decided to appoint Yang Weilai as board secretary, with a term starting from the date of approval by this board meeting until the end of the fourth board's term. In the first half of 2026, Huaxia Eye Hospital achieved revenue of 2.185 billion yuan and net profit attributable to the parent of 292 million yuan.
About megatrends
Aging Population › Hearing / Vision / Dental Talent
Aging Population › Vision & Eye Care Talent
301267.CS · · Neutral Board secretary Cao Naien resigns and Yang Weilai is appointed as replacement; a routine management change with no clear financial driver.
Read original ↗
财中社·2dRead more →
United States
2

Glaukos Reports Three-Year Epioxa Keratoconus Data and RevOpsis Licensing Deal

Glaukos Corporation reported positive three-year extension trial results for its non-invasive keratoconus treatment Epioxa while simultaneously securing an exclusive licensing deal to broaden its retinal disease pipeline. In the GLK-202-03 extension study, 38 study eyes across 35 subjects were followed for up to three years after a single Epioxa treatment with no further medical interventions, and 92% of participant eyes completed the final three-year assessment visit. Treated eyes maintained a 1.9 diopter improvement in maximum corneal curvature from baseline, while 29% of eyes gained two or more lines of best-corrected visual acuity and 20% gained three or more lines, with zero serious adverse events, treatment-related adverse events, or therapy-related discontinuations. Separately, Glaukos announced an exclusive licensing agreement with RevOpsis Therapeutics Inc. to develop and commercialize RO-104, a first-in-class tri-specific biologic targeting neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion, which blocks VEGF-A and VEGF-C while inhibiting Ang-2. The deal grants Glaukos exclusive rights to use the RevMod platform to develop up to four additional retinal biologics, with financial terms not disclosed. Glaukos shares were down 10.76% at $153.65 at the time of publication on Thursday.
About megatrends
Aging Population › Vision & Eye Care Technology
GKOS · Technology · Positive Positive three-year Epioxa keratoconus extension data with durable 1.9 diopter improvement and zero serious adverse events.
GKOS · Demand · Positive Exclusive licensing deal with RevOpsis to develop and commercialize RO-104 and up to four additional retinal biologics, broadening its pipeline.
RevOpsis Therapeutics · Capital · Neutral RevOpsis is the licensor in the exclusive RO-104 deal with Glaukos, but financial terms were not disclosed.
Read original ↗
Benzinga·2dRead more →
China
▼5

Guangzheng Eye Hospital Subsidiary Fined RMB 1.0456 Million for Medical Insurance Settlement Violations

Guangzheng Eye Hospital announced after market close on October 8 that its subsidiary Shanghai New Vision Eye Hospital Co., Ltd. received an administrative penalty decision from the Shanghai Municipal Medical Security Bureau. For including medical expenses that did not fall within the payment scope of the medical security fund in its settlements, causing losses to the fund, it was fined RMB 1.0456 million. The announcement showed that the conduct fell under item 6 of Article 38 of the Regulations on the Supervision and Administration of the Use of Medical Security Funds. As of the disclosure date, Guangzheng Eye Hospital and its controlled subsidiaries had accumulated administrative penalties totaling RMB 1.9712 million over the preceding 12 consecutive months, accounting for 10.11% of the company's most recent audited net profit attributable to the parent. All fines have been paid and recorded in current profit or loss. The company said the penalty will affect operating results for 2026, with the final actual impact subject to the annual audit by its accounting firm, but it will not have a material impact on long-term development and does not trigger mandatory delisting for major violations. The subsidiary hospital has completed special rectification as required, including organizing study of the relevant regulations and medical insurance service agreements, assigning dedicated personnel for medical insurance management, improving oversight procedures, and establishing accountability mechanisms.
About megatrends
Aging Population › Vision & Eye Care ▼Regulation
002524.CS · Regulation · Negative Subsidiary fined RMB 1.0456 million for medical insurance settlement violations, with cumulative penalties of RMB 1.9712 million hitting 10.11% of net profit.
上海新视界眼科医院有限公司 · Regulation · Negative Shanghai New Vision Eye Hospital was fined RMB 1.0456 million by the Shanghai Medical Security Bureau for improper medical insurance fund settlements.
Read original ↗
每日经济新闻·3dRead more →
United States

Bausch + Lomb Advances Oral Dry AMD Treatment After FDA Meeting

Bausch + Lomb said it has made progress developing tonabersat, also known as BL1243, an oral treatment for dry age-related macular degeneration, following a meeting with the US FDA. The company said discussions with the agency yielded greater clarity on the clinical development path for BL1243. Bausch + Lomb added that the FDA supported, in principle, its initial study to evaluate the candidate's safety and how it acts in the body. Assuming that study goes well, tonabersat will move into a phase 2 study in individuals with dry AMD but without advanced retinal damage. The clinical program for tonabersat is slated to begin in 2027.
About megatrends
Aging Population › Vision & Eye Care Technology
BLCO · Technology · Positive FDA meeting yields clarity on clinical path for oral dry AMD candidate tonabersat, advancing its development
Read original ↗
Seeking Alpha·4dRead more →
United StatesJapan
▲

SpyGlass Pharma Acquires Advanced Vision Science for $13 Million

SpyGlass Pharma, Inc. announced today it has acquired all outstanding shares of common stock of Advanced Vision Science, Inc., an ophthalmic medical device company and manufacturer of intraocular lenses and lens materials, for approximately $13 million in cash. AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd. and is the current supplier of the intraocular lens used in SpyGlass Pharma's two Phase 3 registrational trials evaluating the BIM-IOL System. The acquisition secures scalable commercial intraocular lens manufacturing capacity for SpyGlass Pharma's lead product candidate and accelerates its pathway to adding premium lens options into its intraocular-lens-based drug delivery system. Under the agreement, AVS will be the exclusive manufacturer and supplier of several types of intraocular lenses to Santen for commercialization in Japan, and will continue to license its glistening-free hydrophobic acrylic lens material to Bausch + Lomb for use in the enVista intraocular lens line and manufacture products for other global intraocular lens companies. SpyGlass Pharma said it intends to continue supporting AVS customers and licensees utilizing their proprietary intraocular lens material technology, such as Santen, Bausch + Lomb, and other global intraocular lens companies.
About megatrends
Aging Population › Vision & Eye Care ▲Supply
SGP · Supply · Positive SpyGlass acquires AVS, securing scalable commercial intraocular lens manufacturing capacity for its lead BIM-IOL product candidate.
Advanced Vision Science, Inc. · Capital · Positive Advanced Vision Science is acquired by SpyGlass Pharma for approximately $13 million in cash.
4536.JP · · Neutral Santen sold its AVS subsidiary for ~$13M but retains AVS as exclusive manufacturer/supplier of intraocular lenses for commercialization in Japan.
Read original ↗
GlobeNewswire·10dRead more →